Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | IDO1 | P14902 | 7/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | PLEKHA1 | Q9HB21 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL150407 | 0.83 | IDO1 (0.45) | KMT2AIDO1MAPTPOLBHPGD | |
| SCHEMBL14317086 | 0.81 | KMT2A (0.42) | KMT2AIDO1MAPTAKT1BTK | |
| Hydrochloric Acid SCHEMBL19133467 | 0.81 | IDO1 (0.44) | KMT2AIDO1MAPTAKT1BTK | |
| SCHEMBL179219 | 0.77 | — | — | |
| SCHEMBL5359897 | 0.72 | KMT2A (0.36) | KMT2AIDO1MAPTALDH1A1POLB | |
| SCHEMBL12230770 | 0.71 | KMT2A (0.37) | KMT2AIDO1MAPTALDH1A1HTT | |
| SCHEMBL12053000 | 0.70 | IDO1 (0.50) | KMT2AIDO1MAPTALDH1A1IKBKE | |
| SCHEMBL179214 | 0.70 | GAA (0.44) | KMT2AMAPTALDH1A1HTTMCL1 | |
| SCHEMBL17624206 | 0.70 | KMT2A (0.36) | KMT2AIDO1MAPTALDH1A1POLB | |
| SCHEMBL14950078 | 0.70 | ALDH1A1 (0.52) | KMT2AIDO1MAPTALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157476-B2 | Aminofurazan compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1660467-A2 | AMINOFURAZAN COMPOUNDS AS PROTEIN KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050148640-A1 | Aminofurazan compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2005-07-07 | — | — | US | disclosed |
| WO-2005019190-A2 | (4 -AMINO -1,2, 5-OXADIAZOL-4-YL) -HETΞROAROMATIC COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148640-A1 | Aminofurazan compounds useful as protein kinase inhibitors | PHKG1, MAP3K20, MAP3K5 | KMT2A 1498/4885IDO1 2426/4885MAPT 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.